Metocurine

Summary

Metocurine (CHEMBL1259) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 652.8 Da · C40H48N2O6+2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1259
Name	Metocurine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	21233
Molecular formula	C40H48N2O6+2
Molecular weight	652.8
InChIKey	JFXBEKISTKFVAB-AJQTZOPKSA-N

SMILES: C[N+]1(CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C

IUPAC name: (1S,16R)-9,10,21,25-tetramethoxy-15,15,30,30-tetramethyl-7,23-dioxa-15,30-diazoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene

Also known as: Dimethyl tubocurarine, Dimethyltubocurarinium, Metocurine cation, Metocurine ion, metocurine (MTC), Dimethyltubocurarine, Metocurine

Parent form; salt/anhydrous children: CHEMBL1739, CHEMBL2105841

Patent coverage: 162 distinct patent families (510 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 509 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).